African-Led Research Redefines Global HIV Treatment as Drug Resistance Threatens Gains

A groundbreaking African-led study is reshaping the global response to HIV treatment failure and drug resistance, offering renewed hope to millions of people living with HIV across the continent and beyond.

The Ndovu Study, a large multi-country research project underway in Kenya, Tanzania, Lesotho and Mozambique, is generating critical evidence on how to better detect, manage and prevent treatment failure among patients using dolutegravir (DTG)-based HIV regimens — the backbone of modern HIV treatment in Africa and worldwide.

Dolutegravir is a key antiretroviral drug that suppresses HIV, enabling patients to live long, healthy lives and prevent transmission when taken consistently. However, poor adherence to treatment can lead to a rise in viral load, treatment failure and, in some cases, the development of drug resistance. Failure on dolutegravir is particularly alarming because alternative treatment options remain limited, significantly increasing the risk of severe illness and death.

Researchers say non-adherence remains one of the biggest drivers of HIV drug resistance, advanced disease and AIDS-related complications, including life-threatening infections such as tuberculosis and cryptococcal meningitis. Emerging data show that patients failing DTG-based treatment often present with dangerously low CD4 counts and severe opportunistic infections.

The Ndovu Study is addressing these challenges head-on by enrolling people living with HIV who have high viral loads while on dolutegravir, closely monitoring them, supporting adherence, conducting drug-resistance testing and improving the identification and management of advanced HIV disease. The findings are expected to directly inform national, regional and global guidelines on HIV treatment failure.

Despite decades of progress, the global HIV response remains fragile. According to the World Health Organization, an estimated 40.8 million people were living with HIV in 2024, with 1.3 million new infections and 630,000 HIV-related deaths recorded worldwide — underscoring the urgent need to improve the quality of HIV care and clinical decision-making.

From January 26 to 28, 2026, the Centre for Epidemiological Modelling and Analysis (CEMA) hosted principal investigators and partners at a three-day Ndovu Investigators’ Meeting in Naivasha, Kenya. The meeting brought together researchers from participating countries, along with representatives from Ministries of Health and implementing partners, to review progress and align priorities for the next phase of the study.

Ndovu teams are working closely with national HIV programmes to ensure that emerging evidence is rapidly translated into policy and clinical practice. While early findings are promising, researchers say sustained collaboration and continued investment are essential to fully address treatment failure and drug resistance.

The study is sponsored by CEMA at the University of Nairobi in collaboration with the Kenya Ministry of Health, Muhimbili University of Health and Allied Sciences (MUHAS) in Tanzania, SolidarMed in Lesotho, and the Instituto Nacional de Saúde (INS) in Mozambique, with funding from the Bill & Melinda Gates Foundation.

Dr Loice Ombajo, Chief Investigator of the Ndovu Study and Co-Director at CEMA, described the situation as urgent. “It is deeply concerning that some patients are failing treatment due to poor adherence and potential resistance to dolutegravir, placing their lives at risk. This study will provide the evidence needed to guide how such patients should be managed and will inform global HIV treatment guidelines,” she said.

Dr Patricia Munseri, Principal Investigator in Tanzania and Associate Professor at MUHAS, said the team is confident in its ability to generate high-quality data that meets national and international ethical standards and supports evidence-based policy decisions.

In Lesotho, Principal Investigator Dr Irene Ayakaka noted that sustaining gains in HIV treatment requires early detection of drug resistance, routine monitoring and stronger laboratory systems. “The lessons emerging from Ndovu are already shaping high-level discussions and will directly influence national treatment guidelines,” she said.

Dr Nalia Ismael, Principal Investigator in Mozambique, added that while progress has been made in strengthening HIV care, gaps remain in patient retention, adherence and rising drug resistance. “The Ndovu Study is delivering real-world, African-led data that will help national programmes better manage patients persistently failing DTG regimens and improve outcomes,” she said.

With its focus on adherence, resistance and advanced disease, the Ndovu Study is positioning Africa at the forefront of global HIV research — strengthening health systems, shaping policy and saving lives.